Skip to main content

Table 6 The efficiency of serum SV2A combined with other biomarkers in discriminating cognitively unimpaired APOE ε4 carriers from APOE ε4 non-carriers

From: Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer’s disease

 

APOE ε4 −/− vs. APOE ε4 +/−

AUC (95% CI)

Cutoff (pg/mL)

SEN (%)

SPE (%)

 

SV2A

 

0.690 (0.597–0.773)

≤ 4413.00

81.82

48.33

 

NfL

 

0.522 (0.426–0.616)

> 1.1

96.36

18.33

 

GFAP

 

0.622 (0.527–0.711)

> 16.6

32.73

90.00

 

p-tau217

 

0.554 (0.459–0.647)

> 1.8

36.36

81.67

 

SV2A + NfL

 

0.671 (0.577–0.756)

NA

100.0*

55.0†

 

SV2A + GFAP

 

0.728 (0.637–0.807)

NA

89.1*

91.7†

 

SV2A + p-tau217

 

0.685 (0.692–0.769)

NA

92.7*

90.0†

 

SV2A + p-tau217 + GFAP + NfL

 

0.745 (0.655–0.822)

NA

100.0*

98.3†

 
  1. Note: We assessed the normality of the distribution of the variables by the Shapiro–Wilk test. Logistic regression was used to evaluate predictive models and receiver operating characteristic (ROC) curves constructed from the logistic scores. The Youden index was calculated to determine the best cutoff regarding sensitivity and specificity for the single indicator. The *parallel test and †serial test was used to calculate the sensitivity and specificity of the combined diagnostic models, respectively. Abbreviations: 95%CI, 95% confidence interval; APOE ε4 −/−, APOE ε4 non-carriers; APOE ε4 +/−, APOE ε4 carriers; AUC, area under the curve; GFAP, glial fibrillary acidic protein; NfL, neurofilament light; p-tau217, phosphorylated tau; SEN, sensitivity; SPE, specificity; SD, standard deviation; SV2A, synaptic vesicle glycoprotein 2 A; vs., versus
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193